Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 6/20 | 0.41 |
| ▸ | CCND1 | P24385 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.41 |
| ▸ | CCND3 | P30281 | 3/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632891 | 0.80 | JAK2 (0.48) | GRM5KMT2AMEN1POLBMCHR1 | |
| SCHEMBL1633369 | 0.78 | NNMT (0.43) | MCHR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1633395 | 0.75 | CDK2 (0.49) | JAK2JAK1TYK2JAK3CDK4 | |
| SCHEMBL1632814 | 0.74 | CDK2 (0.52) | JAK2JAK1TYK2JAK3CDK4 | |
| SCHEMBL1633421 | 0.74 | MAP3K5 (0.49) | KMT2AMEN1POLBJAK2JAK1 | |
| SCHEMBL1634282 | 0.73 | ACVR1 (0.52) | JAK2JAK1TYK2JAK3CDK2 | |
| SCHEMBL1631342 | 0.73 | CDK2 (0.45) | MCHR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1634323 | 0.73 | JAK2 (0.47) | MCHR1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1633381 | 0.72 | PTK2 (0.54) | JAK2JAK1TYK2JAK3CDK2 | |
| SCHEMBL1634286 | 0.72 | AURKA (0.53) | JAK2JAK1TYK2JAK3CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | GRM5 2527/4885KMT2A 1044/4885MEN1 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.